Calcium channel, voltage-dependent, L type, alpha 1D subunit (also known as Cav1.3) is a protein that in humans is encoded by the CACNA1D gene.[5] Cav1.3 channels belong to the Cav1 family, which form L-type calcium currents and are sensitive to selective inhibition by dihydropyridines (DHP).
Structure and function
edit
Voltage-dependent calcium channels (VDCC) are selectively permeable to calcium ions, mediating the movement of these ions in and out of excitable cells. At resting potential, these channels are closed, but when the membrane potential is depolarised these channels open. The influx of calcium ions into the cell can initiate a myriad of calcium-dependent processes including muscle contraction, gene expression, and secretion. Calcium-dependent processes can be halted by lowering intracellular calcium levels, which, for example, can be accomplished by calcium pumps.[6]
Voltage-dependent calcium channels are multi-proteins composed of α1, β, α2δ and γ subunits. The major subunit is α1, which forms the selectivity pore, voltage-sensor and gating apparatus of VDCCs. In Cav1.3 channels, the α1 subunit is α1D. This subunit differentiates Cav1.3 channels from other members of the Cav1 family, such as the predominant and better-studied Cav1.2, which has an α1C subunit. The significance of the α1 subunit also means that it is the primary _target for calcium-channel blockers such as dihydropyridines. The remaining β, α2δ and γ subunits have auxiliary functions.
The α1 subunit has four homologous domains, each with six transmembrane segments. Within each homologous domain, the fourth transmembrane segment (S4) is positively charged, as opposed to the other five hydrophobic segments. This characteristic enables S4 to function as the voltage-sensor. Alpha-1D subunits belong to the Cav1 family, which is characterised by L-type calcium currents. Specifically, α1D subunits confer low-voltage activation and slowly inactivating Ca2+ currents, ideal for particular physiological functions such as neurotransmitter release in cochlea inner hair cells.
The biophysical properties of Cav1.3 channels are closely regulated by a C-terminal modulatory domain (CTM), which affects both the voltage dependence of activation and Ca2+ dependent inactivation.[7] Cav1.3 have a low affinity for DHP and activate at sub-threshold membrane potentials, making them ideal for a role in cardiac pacemaking.[8]
Regulation
editAlternative splicing
editPost-transcriptional alternative splicing of Cav1.3 is an extensive and vital regulatory mechanism. Alternative splicing can significantly affect the gating properties of the channel. Comparable to alternative splicing of Cav1.2 transcripts, which confers functional specificity,[9] it has recently been discovered that alternative splicing, particularly in the C-terminus, affects the pharmacological properties of Cav1.3.[10][11] Strikingly, up to 8-fold differences in dihydropyridine sensitivity between alternatively spliced isoforms have been reported.[12][13]
Negative feedback
editCav1.3 channels are regulated by negative feedback to achieve Ca2+ homeostasis. Calcium ions are a critical second messenger, intrinsic to intracellular signal transduction. Extracellular calcium levels are approximated to be 12000-fold greater than intracellular levels. During calcium-dependent processes, the intracellular level of calcium rises by up to 100-fold. It is vitally important to regulate this calcium gradient, not least because high levels of calcium are toxic to the cell, and can induce apoptosis.
Ca2+-bound calmodulin (CaM) interacts with Cav1.3 to induce calcium-dependent inactivation (CDI). Recently, it has been shown that RNA editing of Cav1.3 transcripts is essential for CDI.[14] Contrary to expectation, RNA editing does not simply attenuate the binding of CaM, but weakens the pre-binding of Ca2+-free calmodulin (apoCaM) to channels. The upshot is that CDI is continuously tuneable by changes in levels of CaM.
Clinical significance
editHearing
editCav1.3 channels are widely expressed in humans.[15] Notably, their expression predominates in cochlea inner hair cells (IHCs). Cav1.3 have been shown through patch clamp experiments to be essential for normal IHC development and synaptic transmission.[16] Therefore, Cav1.3 are required for proper hearing.[17]
Chromaffin cells
editCav1.3 are densely expressed in chromaffin cells. The low-voltage activation and slow inactivation of these channels makes them ideal for controlling excitability in these cells. Catecholamine secretion from chromaffin cells is particularly sensitive to L-type currents, associated with Cav1.3. Catecholamines have many systemic effects on multiple organs. In addition, L-type channels are responsible for exocytosis in these cells.[18]
Neurodegeneration
editParkinson's disease is the second most common neurodegenerative disease, in which the death of dopamine-producing cells in the substantia nigra of the midbrain leads to impaired motor function, perhaps best characterised by tremor. Recent evidence suggests that L-type Cav1.3 Ca2+ channels contribute to the death of dopaminergic neurones in patients with Parkinson's disease.[8] The basal activity of these neurones is also dependent on L-type Ca2+ channels, such as Cav1.3. Continuous pacemaking activity drives permanent intracellular dendritic and somatic calcium transients, which appears to make the dopaminergic substantia nigra neurones vulnerable to stressors that contribute to their death. Therefore inhibition of L-type channels, in particular Cav1.3 is protective against the pathogenesis of Parkinson's in some animal models.[8][19] A clinical phase III trial (STEADY-PD III Archived 2019-04-07 at the Wayback Machine) testing this hypothesis in patients with early Parkinsons's failed to show efficacy in slowing the progression of Parkinson's.[20]
Inhibition of Cav1.3 can be achieved using calcium channel blockers, such as dihydropyridines (DHPs). These drugs are used since decades to treat arterial hypertension and angina. This is due to their potent vasorelaxant properties, which are mediated by the inhibition of Cav1.2 L-type calcium channels in arterial smooth muscle.[15] Therefore, hypotensive reactions (and leg edema) are regarded dose-limiting side effects when using DHPs for inhibiting Cav1.3 channel in the brain.[21] In the face of this issue, attempts have been made to discover selective Cav1.3 channel blockers. One candidate has been claimed to be a potent and highly selective inhibitor of Cav1.3. This compound, 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione was therefore put forward as a candidate for the future treatment of Parkinson's.[22] However, its selectivity and potency could not be confirmed in two independent studies from two other groups.[23] One of them even reported gating changes induced by this drug., which indicate channel activating rather than blocking effects.[24]
Prostate cancer
editRecent evidence from immunostaining experiments shows that CACNA1D is highly expressed in prostate cancers compared with benign prostate tissues. Blocking L-type channels or knocking down gene expression of CACNA1D significantly suppressed cell-growth in prostate cancer cells.[25] It is important to recognise that this association does not represent a causal link between high levels of α1D protein and prostate cancer. Further investigation is needed to explore the role of CACNA1D gene overexpression in prostate cancer cell growth.
Aldosteronism
editDe novo somatic mutations in conserved regions within the channel's activation gate of its pore-forming α1-subunit (CACNA1D) cause excessive aldosterone production in aldosterone-producing adenomas (APA) resulting in primary aldosteronism, which causes treatment - resistant arterial hypertension. These mutations allow increased Ca2+ influx through Cav1.3, which in turn triggers Ca2+ - dependent aldosterone production.[26][27] The number of validated APA mutations is constantly growing.[28] In rare cases, APA mutations have also been found as germline mutations in individuals with neurodevelopmental disorders of different severity, including autism spectrum disorder.[26][28][29]
See also
editReferences
edit- ^ a b c GRCh38: Ensembl release 89: ENSG00000157388 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000015968 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Entrez Gene: CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit".
- ^ Brown BL, Walker SW, Tomlinson S (August 1985). "Calcium calmodulin and hormone secretion". Clinical Endocrinology. 23 (2): 201–18. doi:10.1111/j.1365-2265.1985.tb00216.x. PMID 2996810. S2CID 45017291.
- ^ Lieb A, Scharinger A, Sartori S, Sinnegger-Brauns MJ, Striessnig J (2012). "Structural determinants of CaV1.3 L-type calcium channel gating". Channels. 6 (3): 197–205. doi:10.4161/chan.21002. PMC 3431584. PMID 22760075.
- ^ a b c Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ (June 2007). "'Rejuvenation' protects neurons in mouse models of Parkinson's disease". Nature. 447 (7148): 1081–6. Bibcode:2007Natur.447.1081C. doi:10.1038/nature05865. PMID 17558391. S2CID 4429534.
- ^ Liao P, Yu D, Lu S, Tang Z, Liang MC, Zeng S, Lin W, Soong TW (November 2004). "Smooth muscle-selective alternatively spliced exon generates functional variation in Cav1.2 calcium channels". The Journal of Biological Chemistry. 279 (48): 50329–35. doi:10.1074/jbc.m409436200. PMID 15381693.
- ^ Singh A, Gebhart M, Fritsch R, Sinnegger-Brauns MJ, Poggiani C, Hoda JC, Engel J, Romanin C, Striessnig J, Koschak A (July 2008). "Modulation of voltage- and Ca2+-dependent gating of CaV1.3 L-type calcium channels by alternative splicing of a C-terminal regulatory domain". The Journal of Biological Chemistry. 283 (30): 20733–44. doi:10.1074/jbc.M802254200. PMC 2475692. PMID 18482979.
- ^ Tan BZ, Jiang F, Tan MY, Yu D, Huang H, Shen Y, Soong TW (December 2011). "Functional characterization of alternative splicing in the C terminus of L-type CaV1.3 channels". The Journal of Biological Chemistry. 286 (49): 42725–35. doi:10.1074/jbc.M111.265207. PMC 3234967. PMID 21998309.
- ^ Huang H, Yu D, Soong TW (October 2013). "C-terminal alternative splicing of CaV1.3 channels distinctively modulates their dihydropyridine sensitivity". Molecular Pharmacology. 84 (4): 643–53. doi:10.1124/mol.113.087155. PMID 23924992. S2CID 22439331.
- ^ Ortner NJ, Bock G, Dougalis A, Kharitonova M, Duda J, Hess S, Tuluc P, Pomberger T, Stefanova N, Pitterl F, Ciossek T, Oberacher H, Draheim HJ, Kloppenburg P, Liss B, Striessnig J (July 2017). "2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease". The Journal of Neuroscience. 37 (28): 6761–6777. doi:10.1523/JNEUROSCI.2946-16.2017. PMC 6596555. PMID 28592699.
- ^ Bazzazi H, Ben Johny M, Adams PJ, Soong TW, Yue DT (October 2013). "Continuously tunable Ca(2+) regulation of RNA-edited CaV1.3 channels". Cell Reports. 5 (2): 367–77. doi:10.1016/j.celrep.2013.09.006. PMC 4349392. PMID 24120865.
- ^ a b Zamponi GW, Striessnig J, Koschak A, Dolphin AC (October 2015). "The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential". Pharmacological Reviews. 67 (4): 821–70. doi:10.1124/pr.114.009654. PMC 4630564. PMID 26362469.
- ^ Brandt A, Striessnig J, Moser T (November 2003). "CaV1.3 channels are essential for development and presynaptic activity of cochlear inner hair cells". The Journal of Neuroscience. 23 (34): 10832–40. doi:10.1523/JNEUROSCI.23-34-10832.2003. PMC 6740966. PMID 14645476.
- ^ Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, Striessnig J (July 2000). "Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels". Cell. 102 (1): 89–97. doi:10.1016/S0092-8674(00)00013-1. PMID 10929716. S2CID 17923472.
- ^ Vandael DH, Mahapatra S, Calorio C, Marcantoni A, Carbone E (July 2013). "Cav1.3 and Cav1.2 channels of adrenal chromaffin cells: emerging views on cAMP/cGMP-mediated phosphorylation and role in pacemaking". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1828 (7): 1608–18. doi:10.1016/j.bbamem.2012.11.013. hdl:2318/132208. PMID 23159773.
- ^ Liss B, Striessnig J (January 2019). "The Potential of L-Type Calcium Channels as a Drug _target for Neuroprotective Therapy in Parkinson's Disease". Annual Review of Pharmacology and Toxicology. 59 (1): 263–289. doi:10.1146/annurev-pharmtox-010818-021214. PMID 30625283. S2CID 58619079.
- ^ Hoffman M (5 May 2019). "Isradipine Fails to Slow Early Parkinson Disease Progression in Phase 3 Study". NeurologyLive. Retrieved 2019-11-25.
- ^ Parkinson Study Group (November 2013). "Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)". Movement Disorders. 28 (13): 1823–31. doi:10.1002/mds.25639. PMID 24123224. S2CID 9594193.
- ^ Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, Silverman RB (2012). "CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease". Nature Communications. 3: 1146. Bibcode:2012NatCo...3.1146K. doi:10.1038/ncomms2149. PMID 23093183.
- ^ Huang H, Ng CY, Yu D, Zhai J, Lam Y, Soong TW (July 2014). "Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent". Nature Communications. 5: 4481. Bibcode:2014NatCo...5.4481H. doi:10.1038/ncomms5481. PMC 4124865. PMID 25057870.Ortner NJ, Bock G, Vandael DH, Mauersberger R, Draheim HJ, Gust R, Carbone E, Tuluc P, Striessnig J (June 2014). "Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators". Nature Communications. 5: 3897. Bibcode:2014NatCo...5.3897O. doi:10.1038/ncomms4897. PMC 4083433. PMID 24941892.
- ^ Ortner NJ, Bock G, Vandael DH, Mauersberger R, Draheim HJ, Gust R, Carbone E, Tuluc P, Striessnig J (June 2014). "Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators". Nature Communications. 5: 3897. Bibcode:2014NatCo...5.3897O. doi:10.1038/ncomms4897. PMC 4083433. PMID 24941892.
- ^ Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Thrasher JB, Li B (July 2014). "Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers". Urologic Oncology. 32 (5): 524–36. doi:10.1016/j.urolonc.2013.05.011. PMID 24054868.
- ^ a b Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Åkerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP (September 2013). "Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism". Nature Genetics. 45 (9): 1050–4. doi:10.1038/ng.2695. PMC 3876926. PMID 23913001.
- ^ Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Küsters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ (September 2013). "Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension". Nature Genetics. 45 (9): 1055–60. doi:10.1038/ng.2716. PMID 23913004. S2CID 205347424.
- ^ a b Pinggera A, Striessnig J (October 2016). "2+ channel dysfunction in CNS disorders". The Journal of Physiology. 594 (20): 5839–5849. doi:10.1113/JP270672. PMC 4823145. PMID 26842699.
- ^ Pinggera A, Negro G, Tuluc P, Brown MJ, Lieb A, Striessnig J (January 2018). "2+ channels". Channels. 12 (1): 388–402. doi:10.1080/19336950.2018.1546518. PMC 6287693. PMID 30465465.
Further reading
edit- Williams ME, Feldman DH, McCue AF, Brenner R, Velicelebi G, Ellis SB, Harpold MM (January 1992). "Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype". Neuron. 8 (1): 71–84. doi:10.1016/0896-6273(92)90109-Q. PMID 1309651. S2CID 39341712.
- Seino S, Chen L, Seino M, Blondel O, Takeda J, Johnson JH, Bell GI (January 1992). "Cloning of the alpha 1 subunit of a voltage-dependent calcium channel expressed in pancreatic beta cells". Proceedings of the National Academy of Sciences of the United States of America. 89 (2): 584–8. Bibcode:1992PNAS...89..584S. doi:10.1073/pnas.89.2.584. PMC 48283. PMID 1309948.
- Seino S, Yamada Y, Espinosa R, Le Beau MM, Bell GI (August 1992). "Assignment of the gene encoding the alpha 1 subunit of the neuroendocrine/brain-type calcium channel (CACNL1A2) to human chromosome 3, band p14.3". Genomics. 13 (4): 1375–7. doi:10.1016/0888-7543(92)90078-7. PMID 1324226.
- Chin HM, Kozak CA, Kim HL, Mock B, McBride OW (December 1991). "A brain L-type calcium channel alpha 1 subunit gene (CCHL1A2) maps to mouse chromosome 14 and human chromosome 3". Genomics (Submitted manuscript). 11 (4): 914–9. doi:10.1016/0888-7543(91)90014-6. PMID 1664412.
- Mori Y, Friedrich T, Kim MS, Mikami A, Nakai J, Ruth P, Bosse E, Hofmann F, Flockerzi V, Furuichi T (April 1991). "Primary structure and functional expression from complementary DNA of a brain calcium channel". Nature. 350 (6317): 398–402. Bibcode:1991Natur.350..398M. doi:10.1038/350398a0. PMID 1849233. S2CID 4370532.
- Yamada Y, Masuda K, Li Q, Ihara Y, Kubota A, Miura T, Nakamura K, Fujii Y, Seino S, Seino Y (May 1995). "The structures of the human calcium channel alpha 1 subunit (CACNL1A2) and beta subunit (CACNLB3) genes". Genomics. 27 (2): 312–9. doi:10.1006/geno.1995.1048. PMID 7557998.
- Puro DG, Hwang JJ, Kwon OJ, Chin H (April 1996). "Characterization of an L-type calcium channel expressed by human retinal Müller (glial) cells". Brain Research. Molecular Brain Research (Submitted manuscript). 37 (1–2): 41–8. doi:10.1016/0169-328X(96)80478-5. PMID 8738134.
- Yang SN, Larsson O, Bränström R, Bertorello AM, Leibiger B, Leibiger IB, Moede T, Köhler M, Meister B, Berggren PO (August 1999). "Syntaxin 1 interacts with the L(D) subtype of voltage-gated Ca(2+) channels in pancreatic beta cells". Proceedings of the National Academy of Sciences of the United States of America. 96 (18): 10164–9. doi:10.1073/pnas.96.18.10164. PMC 17860. PMID 10468580.
- Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nürnberg B, Dolphin AC (February 2001). "Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents". Journal of Neurophysiology. 85 (2): 816–27. doi:10.1152/jn.2001.85.2.816. PMID 11160515. S2CID 147295966.
- Rosenthal R, Thieme H, Strauss O (April 2001). "Fibroblast growth factor receptor 2 (FGFR2) in brain neurons and retinal pigment epithelial cells act via stimulation of neuroendocrine L-type channels (Ca(v)1.3)". FASEB Journal. 15 (6): 970–7. doi:10.1096/fj.00-0188com. PMID 11292657.
- Davare MA, Avdonin V, Hall DD, Peden EM, Burette A, Weinberg RJ, Horne MC, Hoshi T, Hell JW (July 2001). "A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2". Science. 293 (5527): 98–101. doi:10.1126/science.293.5527.98. PMID 11441182.
- Namkung Y, Skrypnyk N, Jeong MJ, Lee T, Lee MS, Kim HL, Chin H, Suh PG, Kim SS, Shin HS (October 2001). "Requirement for the L-type Ca(2+) channel alpha(1D) subunit in postnatal pancreatic beta cell generation". The Journal of Clinical Investigation. 108 (7): 1015–22. doi:10.1172/JCI13310. PMC 200955. PMID 11581302.
- Stokes L, Gordon J, Grafton G (May 2004). "Non-voltage-gated L-type Ca2+ channels in human T cells: pharmacology and molecular characterization of the major alpha pore-forming and auxiliary beta-subunits". The Journal of Biological Chemistry. 279 (19): 19566–73. doi:10.1074/jbc.M401481200. PMID 14981074.
- Qu Y, Baroudi G, Yue Y, Boutjdir M (June 2005). "Novel molecular mechanism involving alpha1D (Cav1.3) L-type calcium channel in autoimmune-associated sinus bradycardia". Circulation. 111 (23): 3034–41. doi:10.1161/CIRCULATIONAHA.104.517326. PMID 15939813.
- Baroudi G, Qu Y, Ramadan O, Chahine M, Boutjdir M (October 2006). "Protein kinase C activation inhibits Cav1.3 calcium channel at NH2-terminal serine 81 phosphorylation site". American Journal of Physiology. Heart and Circulatory Physiology. 291 (4): H1614-22. doi:10.1152/ajpheart.00095.2006. PMID 16973824. S2CID 863259.
- Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M (November 2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell. 127 (3): 635–48. doi:10.1016/j.cell.2006.09.026. PMID 17081983. S2CID 7827573.
External links
edit- CACNA1D+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Overview of all the structural information available in the PDB for UniProt: Q01668 (Voltage-dependent L-type calcium channel subunit alpha-1D) at the PDBe-KB.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.